Who is sponsoring NCT06435858?

NCT06435858 is sponsored by Cantonal Hospital Graubuenden.

What drugs are being tested in NCT06435858?

Interventions in NCT06435858: Empagliflozin, Placebo.

What condition does NCT06435858 study?

NCT06435858 studies Autosomal Dominant Polycystic Kidney Disease.

Is NCT06435858 still recruiting?

NCT06435858 is currently recruiting now. Last updated 8 September 2025.

Last reviewed 2025-09-08 · How we verify

NCT06435858: SIDIA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease

Recruiting now Phase 2 Last updated 8 September 2025

What this trial tests

Phase 2 trial testing Empagliflozin in Autosomal Dominant Polycystic Kidney Disease in 40 participants. Currently enrolling.

Timeline

1 September 2024

Primary endpoint
1 July 2025

1 October 2025

Quick facts

Lead sponsor	Cantonal Hospital Graubuenden
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	40
Start date	1 September 2024
Primary completion	1 July 2025
Estimated completion	1 October 2025
Sites	2 locations across Switzerland

Drugs / interventions tested

Empagliflozin (empagliflozin) — full drug profile →
Placebo

Conditions studied

Autosomal Dominant Polycystic Kidney Disease — all drugs for Autosomal Dominant Polycystic Kidney Disease →

Sponsor

Cantonal Hospital Graubuenden

Who can join

Adults 18 to 75, any sex, with Autosomal Dominant Polycystic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Primary Outcome
Time frame: After a two week intervention
\- Calcium, phosphate, magnesium excretion

Sponsor's own description

This study aims to better understand electrolyte handling in patients with autosomal dominant polycystic kidney disease treated with the SGLT2 inhibitor Empagliflozin. Patients will be randomized into two groups and take Empagliflozin or a Placebo for 2 weeks with a wash-out period of 2 weeks. The primary outcome is tubular handling of the divalent ions calcium, phosphate and magnesium. Secondary outcomes include diuresis, safety and tolerability.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

SGLT2 inhibition for patients with ADPKD - closing the evidence gap.
Müller RU, Guerrot D, Chonchol M, Schmitt R, et al · · 2025 · cited 10× · PMID 40199734 · DOI 10.1093/ndt/gfaf061
Interventions for preventing the progression of autosomal dominant polycystic kidney disease.
St Pierre K, Cashmore BA, Bolignano D, Zoccali C, et al · · 2024 · cited 7× · PMID 39356039 · DOI 10.1002/14651858.cd010294.pub3

Verify or expand the search:

Other trials of Empagliflozin

Trials testing the same drug.

NCT07060417 — Vascular Effects of SGLT2i in Non-diabetic CKD · Phase 2 · not yet recruiting
NCT06625073 — Randomized Trial of SGLT2i in Heart Transplant Recipients · Phase 4 · recruiting
NCT07107945 — A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease · Phase 3 · recruiting
NCT07214818 — SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome · Phase 2, PHASE3 · active not recruiting
NCT07180745 — Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease · Phase 4 · not yet recruiting

Other recruiting trials for Autosomal Dominant Polycystic Kidney Disease

Currently open trials in the same condition.

NCT07228364 — Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease · Phase 1 · recruiting
NCT07217158 — Role of ROS and cAMP-PKA Biomarkers in ADPKD · active not recruiting
NCT06065852 — National Registry of Rare Kidney Diseases · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06435858 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cantonal Hospital Graubuenden
Last refreshed: 8 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06435858.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing